A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study, in Healthy Adult Participants and Open-Label Single Ascending Dose Study in Adults With Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Evaluate the Safety and Tolerability of RCT1100
Latest Information Update: 08 May 2025
At a glance
- Drugs RCT 1100 (Primary)
- Indications Primary ciliary dyskinesia
- Focus Adverse reactions; First in man
- Sponsors ReCode Therapeutics
Most Recent Events
- 29 Apr 2025 Status changed from active, no longer recruiting to completed.
- 12 Sep 2024 Planned End Date changed from 21 Dec 2024 to 25 Jan 2025.
- 12 Sep 2024 Status changed from recruiting to active, no longer recruiting.